Anti-Amyloid Monoclonal Antibody Drugs Continue to Show Promise Treating Alzheimer Disease
New anti-amyloid monoclonal antibody drugs for Alzheimer disease have produced encouraging results in targeting the accumulation of amyloid beta plaques; however, questions remain regarding the risk-benefit profile and cost implications.
Olatunji Gbadebo Iwatsubot Lecanemab Wolters Kluwer Health Inc Philo Daniel Early Alzheimer Antibodies Directed Against Amyloid
Source: pharmacytimes.com